I spoke with Moderna $MRNA CEO Stéphane Bancel about intismeran and what's next for the cancer vaccine and the biotech he runs.
"We know the clinical impact in the Phase 3 study is real and big, so we need to go and be aggressive. We need to explore the biology. There will be some risk, because it’s not going to work everywhere."
Read the Q&A:
#ESMO26#
显示更多
